As of 2021, Alzheimer’s Disease (AD) afflicts 6.2 million Americans. This number is expected to climb rapidly in the coming decades as the number of individuals at the age of increased risk rises. AD is characterized by the deposition of insoluble, β-sheet-rich amyloid plaques of the amyloid β (Aβ) peptide. However, the AD-causing toxicity of Aβ is mediated by soluble, oligomeric species of the peptide formed in the process of aggregating into plaques (amyloidogenesis). These oligomers have been shown to adopt a unique secondary structure known as “α-sheet.” The onset of AD is typically sporadic, but some cases, known as familial Alzheimer’s Disease (FAD), are inherited via mutations in Aβ. None of these mutations have been studied for their ability to adopt the pathogenic α-sheet conformation. Therefore, I am investigating the impact of the Arctic (E22G), Iowa (D23N), Flemish (A21G), and Osaka (E22Δ) mutations on the amyloidogenesis and toxicity of Aβ to explain their role in FAD. I accomplish this through a Soluble Oligomer Binding Assay (SOBA) designed in the Daggett Lab to capture and quantify α-sheet conformations. Additionally I use circular dichroism, MTT cell toxicity assays and Thioflavin-T curves to investigate the aggregation pathway of these mutants. I have found that these mutations confer unique aggregation patterns to Aβ. Many of these Aβ mutants appear to adopt a stabilized α-sheet consistent with their tie to FAD. This provides an explanation of how these mutants cause FAD and offers insight into the factors that contribute to the adoption of α-sheet structure and pathogenesis of AD.